NCT05357027View on ClinicalTrials.gov

HPV16 E6 TCR T Cells for Cervical Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

August 31, 2025

Conditions
Cervical Carcinoma
Interventions
BIOLOGICAL

TC-E202 cells

T cells genetically engineered with a TCR targeting HPV16 E6 (E6 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells

DRUG

IL-2

Following cell infusion, the patient receives high-dose bolus IL-2, which is dosed to individual patient tolerance. IL-2 improves the survival of TC-E202 cells after infusion.

DRUG

Fludarabine

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

DRUG

Cyclophosphamide Capsules

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Trial Locations (1)

400000

RECRUITING

Xiaochun Cheng, Chongqing

All Listed Sponsors
collaborator

Fudan University

OTHER

lead

TCRCure Biopharma Ltd.

INDUSTRY